Literature DB >> 20653066

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.

Naohiko Kohya1, Kenji Kitahara, Kohji Miyazaki.   

Abstract

AIM: To evaluate the adequacy of surgical treatment of T2 gallbladder carcinoma (GBCa) according to tumor spread in the subserosal layer.
METHODS: A series of 84 patients with GBCa were treated at Saga University Hospital, Japan between April 1989 and October 2008. The tumor stage was graded according to the TNM staging for GBCa from the American Joint Committee on Cancer Manual 6th edition. Tumor staging revealed 30 patients with T2 tumors. T2 GBCa was divided into three groups histologically by the extent of tumor spread in the subserosal layer, using a score of ss minimum (ss min), ss medium (ss med) or ss massive (ss mas).
RESULTS: For ss min GBCa, there was no positive pathological factor and patient survival was satisfactory with simple cholecystectomy, with or without extra-hepatic bile duct resection. For ss med GBCa, some pathological factors, h-inf (hepatic infiltration), ly (lymphatic invasion) and n (lymph node metastasis), were positive. For ss mas GBCa, there was a high incidence of positive pathological factors. The patient group with extra-hepatic bile duct resection with D2 lymph node dissection (BDR with D2) and those with S4a5 hepatectomy had significantly better survival rates.
CONCLUSION: We suggest that radical surgery is not necessary for ss min GBCa, and partial hepatectomy and BDR are necessary for both ss med and ss mas GBCa.

Entities:  

Mesh:

Year:  2010        PMID: 20653066      PMCID: PMC2909557          DOI: 10.3748/wjg.v16.i28.3567

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

1.  Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

Authors:  V Gebbia; F Giuliani; E Maiello; G Colucci; F Verderame; N Borsellino; G Mauceri; M Caruso; M L Tirrito; M Valdesi
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

2.  Clinical significance of lymph node micrometastasis in gallbladder carcinoma.

Authors:  S Nagakura; Y Shirai; N Yokoyama; K Hatakeyama
Journal:  Surgery       Date:  2001-06       Impact factor: 3.982

3.  Early gallbladder carcinoma does not warrant radical resection.

Authors:  T Wakai; Y Shirai; N Yokoyama; S Nagakura; H Watanabe; K Hatakeyama
Journal:  Br J Surg       Date:  2001-05       Impact factor: 6.939

4.  Radical resection improves survival for patients with pT2 gallbladder carcinoma.

Authors:  P E Wise; Y Y Shi; M K Washington; W C Chapman; J K Wright; K W Sharp; C W Pinson
Journal:  Am Surg       Date:  2001-11       Impact factor: 0.688

5.  Extensive surgery for carcinoma of the gallbladder.

Authors:  S Kondo; Y Nimura; N Hayakawa; J Kamiya; M Nagino; K Uesaka
Journal:  Br J Surg       Date:  2002-02       Impact factor: 6.939

6.  Radical second resection provides survival benefit for patients with T2 gallbladder carcinoma first discovered after laparoscopic cholecystectomy.

Authors:  Toshifumi Wakai; Yoshio Shirai; Katsuyoshi Hatakeyama
Journal:  World J Surg       Date:  2002-04-18       Impact factor: 3.352

Review 7.  Surgical indications and extent of resection in gallbladder cancer.

Authors:  Margo Shoup; Yuman Fong
Journal:  Surg Oncol Clin N Am       Date:  2002-10       Impact factor: 3.495

Review 8.  Cancers of the gallbladder and biliary ducts.

Authors:  Kevin Yee; Brett C Sheppard; John Domreis; Charles D Blanke
Journal:  Oncology (Williston Park)       Date:  2002-07       Impact factor: 2.990

Review 9.  Extended surgery in bilio-pancreatic cancer: the Japanese experience.

Authors:  Yuji Nimura
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

10.  Worldwide trends in mortality from biliary tract malignancies.

Authors:  Tushar Patel
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

View more
  7 in total

1.  Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.

Authors:  Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Role of cholecystectomy and lymph node dissection in patients with T2 gallbladder cancer.

Authors:  Dong Hyun Kim; Sung Hoon Kim; Gi Hong Choi; Chang Moo Kang; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

3.  Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study.

Authors:  Junichi Shindoh; Xabier de Aretxabala; Thomas A Aloia; Juan Carlos Roa; Ivan Roa; Giuseppe Zimmitti; Milind Javle; Claudius Conrad; Dipen M Maru; Taku Aoki; Luca Vigano; Dario Ribero; Norihiro Kokudo; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2015-04       Impact factor: 12.969

4.  Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions.

Authors:  Keita Kai; Naohiko Kohya; Kenji Kitahara; Masanori Masuda; Atsushi Miyoshi; Takao Ide; Osamu Tokunaga; Kohji Miyazaki; Hirokazu Noshiro
Journal:  Virchows Arch       Date:  2011-07-22       Impact factor: 4.064

Review 5.  Gallbladder cancer: Clinical and pathological approach.

Authors:  Keita Kai; Shinichi Aishima; Kohji Miyazaki
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337

6.  Surgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer.

Authors:  Sung Ha Lee; Jae Do Yang; Hong Pil Hwang; Hee Chul Yu; Baik Hwan Cho
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-05-31

Review 7.  To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer?

Authors:  Paschalis Gavriilidis; Alan Askari; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2016-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.